Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 83

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2018

Summary

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Peroxisome proliferator-activated receptor delta is a nuclear receptor that in humans is encoded by the PPARD gene. PPAR-delta is a nuclear hormone receptor that governs a variety of biological processes and involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis, and cancer. The expression of this gene is found to be elevated in colorectal cancer cells. The elevated expression can be repressed by adenomatosis polyposis coli (APC), a tumor suppressor protein involved in the APC/beta-catenin signaling pathway.

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 4, 3 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Genetic Disorders, Immunology, Musculoskeletal Disorders, Oncology, Ophthalmology, Respiratory and Undisclosed which include indications Non-Alcoholic Steatohepatitis (NASH), Acute Renal Failure (ARF) (Acute Kidney Injury), Duchenne Muscular Dystrophy, Dyslipidemia, Liver Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Primary Biliary Cirrhosis, Type 2 Diabetes, Alzheimer's Disease, Bone Disorders, Bone Fracture, Colitis, Familial Chylomicronemia (Type I Hyperlipoproteinemia), Homozygous Familial Hypercholesterolemia (HoFH), Hypertriglyceridemia, Idiopathic Pulmonary Fibrosis, Inflammation, Keratoconjunctivitis sicca (Dry Eye), Kidney Disease, Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Metabolic Syndrome, Mitochondrial Diseases, Neurodegenerative Diseases, Osteoarthritis, Osteoporosis, Parkinson's Disease, Systemic Sclerosis (Scleroderma) and Unspecified.

The latest report Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H2 2018, outlays comprehensive information on the Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)

- The report reviews Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics and enlists all their major and minor projects

- The report assesses Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Overview
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Companies Involved in Therapeutics Development
Chipscreen Biosciences Ltd
CymaBay Therapeutics Inc
Genfit SA
Inventiva
Mitobridge Inc
Nippon Chemiphar Co Ltd
Senju Pharmaceutical Co Ltd
T3D Therapeutics Inc
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Drug Profiles
CS-038 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fonadelpar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HPP-593 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanifibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-0204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-0211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTB-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize PPAR Delta for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-3D959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Dormant Products
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Discontinued Products
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Product Development Milestones
Featured News & Press Releases
Jun 27, 2018: GENFIT: New Preclinical Data Shows Elafibranor Inhibits Development of NAFLD/NASH-Related Cancer
Jun 20, 2018: FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
Jun 19, 2018: CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018
May 31, 2018: GENFIT: Announces the Nomination of Pascal Prigent as Executive Vice President Marketing and Commercial Development
May 08, 2018: CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis
Apr 23, 2018: GENFIT : Positive Outcome from the 24-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
Apr 11, 2018: CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018
Apr 11, 2018: GENFIT: Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort
Apr 03, 2018: Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
Mar 28, 2018: GENFIT: Presentations at EASL 2018 Annual Congress Highlight Progress in NASH Diagnostics, Combination Therapies and Deep-learning Applications in Medical Imaging
Mar 28, 2018: Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors
Mar 13, 2018: Inventiva's paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society
Jan 23, 2018: GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
Jan 08, 2018: CymaBay Therapeutics: Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis
Jan 04, 2018: Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Chipscreen Biosciences Ltd, H2 2018
Pipeline by CymaBay Therapeutics Inc, H2 2018
Pipeline by Genfit SA, H2 2018
Pipeline by Inventiva, H2 2018
Pipeline by Mitobridge Inc, H2 2018
Pipeline by Nippon Chemiphar Co Ltd, H2 2018
Pipeline by Senju Pharmaceutical Co Ltd, H2 2018
Pipeline by T3D Therapeutics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
  • 2018-2023 Global Liquid Biopsy Products Consumption Market Report
    Published: 17-Jul-2018        Price: US 4660 Onwards        Pages: 158
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Liquid Biopsy Products market for 2018-2023. Liquid biopsies are a sequencing-based technology used to screen blood for tiny fragments of genetic material released by cancer tissue, known as circulating tumor (ct) DNA. This report mainly covers the Liquid Biopsy Products product type by technology (circulating Tumor Cells (CTCs), circulating ......
  • 2018 Top 5 Liquid Biopsy Products Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 17-Jul-2018        Price: US 4960 Onwards        Pages: 143
    Liquid biopsies are a sequencing-based technology used to screen blood for tiny fragments of genetic material released by cancer tissue, known as circulating tumor (ct) DNA. This report mainly covers the Liquid Biopsy Products product type by technology (circulating Tumor Cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (or exosomes)), by sample type (blood, urine and other bio fluids (Tissue fluids and Saliva based)), while we can also offer any product sur......
  • Global Vinpocetine Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 135
    Vinpocetine is a synthetic derivative of the vinca alkaloid vincamine, an extract from the lesser periwinkle plant. Vinpocetine was first isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. The mass production of the synthetic compound was started in 1978 by the Hungarian pharmaceutical company Richter Gedeon. The indications is improvement all symptoms of cerebral infarction and cerebral hemorrhage sequela, cerebrovascular atherosclerosis Scope of the Report:......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Vinpocetine Market 2018, Forecast to 2023
    Published: 17-Jul-2018        Price: US 4880 Onwards        Pages: 128
    Vinpocetine is a synthetic derivative of the vinca alkaloid vincamine, an extract from the lesser periwinkle plant. Vinpocetine was first isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. The mass production of the synthetic compound was started in 1978 by the Hungarian pharmaceutical company Richter Gedeon. The indications is improvement all symptoms of cerebral infarction and cerebral hemorrhage sequela, cerebrovascular atherosclerosis Scope of the Report:......
  • Global Rituxan Market Research Report 2018
    Published: 17-Jul-2018        Price: US 2900 Onwards        Pages: 90
    This report studies the global Rituxan market status and forecast, categorizes the global Rituxan market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Rituxan market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major manufacturers cove......
  • Global Nilotinib Market Research Report 2018
    Published: 17-Jul-2018        Price: US 2900 Onwards        Pages: 98
    This report studies the global Nilotinib market status and forecast, categorizes the global Nilotinib market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Nilotinib market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major manufacturer......
  • Global Bone Morphogenetic Protein (BMP) 2 Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 117
    Bone morphogenetic proteins (BMPs) are naturally occurring proteins found in the human body. This family of proteins is involved in a myriad of cellular responses. Certain BMPs are osteoinductive—one of the three main categories of bone grafts—and play an active role in bone formation and maintenance. Scope of the Report: This report focuses on the Bone Morphogenetic Protein (BMP) 2 in global market, especially in North America, Europe and Asia-Pacific, South America, Middl......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Bone Morphogenetic Protein (BMP) 2 Market 2018, Forecast to 2023
    Published: 17-Jul-2018        Price: US 4880 Onwards        Pages: 115
    Bone morphogenetic proteins (BMPs) are naturally occurring proteins found in the human body. This family of proteins is involved in a myriad of cellular responses. Certain BMPs are osteoinductive—one of the three main categories of bone grafts—and play an active role in bone formation and maintenance. Scope of the Report: This report focuses on the Bone Morphogenetic Protein (BMP) 2 in global market, especially in North America, Europe and Asia-Pacific, South America, Middl......
  • Global Bacillus Coagulans Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 137
    Bacillus Coagulans is a lactic acid-forming bacterial species within the genus Bacillus. The organism was first isolated and described as Bacillus Coagulans in 1915 by B.W. Hammer at the Iowa Agricultural Experiment Station as a cause of an outbreak of coagulation in evaporated milk packed by an Iowa condensary. Separately isolated in 1935 and described as Lactobacillus sporogenes in the fifth edition of Bergey's Manual, it exhibits characteristics typical of both genera Lactobacillus and Bacill......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs